Request for Covid-19 Impact Assessment of this Report
The United States Urological Cancer Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Urological Cancer Drugs market, reaching US$ million by the year 2028. As for the Europe Urological Cancer Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Urological Cancer Drugs players cover Novartis, Pfizer, Johnson & Johnson, and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Urological Cancer Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Tablets
Injection
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Urological Cancer Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Urological Cancer Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Urological Cancer Drugs by Country/Region, 2017, 2022 & 2028
2.2 Urological Cancer Drugs Segment by Type
2.2.1 Tablets
2.2.2 Injection
2.3 Urological Cancer Drugs Sales by Type
2.3.1 Global Urological Cancer Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Urological Cancer Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Urological Cancer Drugs Sale Price by Type (2017-2022)
2.4 Urological Cancer Drugs Segment by Application
2.4.1 Prostate Cancer
2.4.2 Bladder Cancer
2.4.3 Kidney Cancer
2.4.4 Testicular Cancer
2.4.5 Others
2.5 Urological Cancer Drugs Sales by Application
2.5.1 Global Urological Cancer Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Urological Cancer Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Urological Cancer Drugs Sale Price by Application (2017-2022)
3 Global Urological Cancer Drugs by Company
3.1 Global Urological Cancer Drugs Breakdown Data by Company
3.1.1 Global Urological Cancer Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Urological Cancer Drugs Sales Market Share by Company (2020-2022)
3.2 Global Urological Cancer Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Urological Cancer Drugs Revenue by Company (2020-2022)
3.2.2 Global Urological Cancer Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Urological Cancer Drugs Sale Price by Company
3.4 Key Manufacturers Urological Cancer Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urological Cancer Drugs Product Location Distribution
3.4.2 Players Urological Cancer Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Urological Cancer Drugs by Geographic Region
4.1 World Historic Urological Cancer Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Urological Cancer Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Urological Cancer Drugs Annual Revenue by Geographic Region
4.2 World Historic Urological Cancer Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Urological Cancer Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Urological Cancer Drugs Annual Revenue by Country/Region
4.3 Americas Urological Cancer Drugs Sales Growth
4.4 APAC Urological Cancer Drugs Sales Growth
4.5 Europe Urological Cancer Drugs Sales Growth
4.6 Middle East & Africa Urological Cancer Drugs Sales Growth
5 Americas
5.1 Americas Urological Cancer Drugs Sales by Country
5.1.1 Americas Urological Cancer Drugs Sales by Country (2017-2022)
5.1.2 Americas Urological Cancer Drugs Revenue by Country (2017-2022)
5.2 Americas Urological Cancer Drugs Sales by Type
5.3 Americas Urological Cancer Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urological Cancer Drugs Sales by Region
6.1.1 APAC Urological Cancer Drugs Sales by Region (2017-2022)
6.1.2 APAC Urological Cancer Drugs Revenue by Region (2017-2022)
6.2 APAC Urological Cancer Drugs Sales by Type
6.3 APAC Urological Cancer Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Urological Cancer Drugs by Country
7.1.1 Europe Urological Cancer Drugs Sales by Country (2017-2022)
7.1.2 Europe Urological Cancer Drugs Revenue by Country (2017-2022)
7.2 Europe Urological Cancer Drugs Sales by Type
7.3 Europe Urological Cancer Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Urological Cancer Drugs by Country
8.1.1 Middle East & Africa Urological Cancer Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Urological Cancer Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Urological Cancer Drugs Sales by Type
8.3 Middle East & Africa Urological Cancer Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urological Cancer Drugs
10.3 Manufacturing Process Analysis of Urological Cancer Drugs
10.4 Industry Chain Structure of Urological Cancer Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urological Cancer Drugs Distributors
11.3 Urological Cancer Drugs Customer
12 World Forecast Review for Urological Cancer Drugs by Geographic Region
12.1 Global Urological Cancer Drugs Market Size Forecast by Region
12.1.1 Global Urological Cancer Drugs Forecast by Region (2023-2028)
12.1.2 Global Urological Cancer Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Urological Cancer Drugs Forecast by Type
12.7 Global Urological Cancer Drugs Forecast by Application
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Urological Cancer Drugs Product Offered
13.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Urological Cancer Drugs Product Offered
13.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Urological Cancer Drugs Product Offered
13.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Urological Cancer Drugs Product Offered
13.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Astellas
13.5.1 Astellas Company Information
13.5.2 Astellas Urological Cancer Drugs Product Offered
13.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Astellas Main Business Overview
13.5.5 Astellas Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Urological Cancer Drugs Product Offered
13.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Abbott Laboratories
13.7.1 Abbott Laboratories Company Information
13.7.2 Abbott Laboratories Urological Cancer Drugs Product Offered
13.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Abbott Laboratories Main Business Overview
13.7.5 Abbott Laboratories Latest Developments
13.8 Celgene Corporation
13.8.1 Celgene Corporation Company Information
13.8.2 Celgene Corporation Urological Cancer Drugs Product Offered
13.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Celgene Corporation Main Business Overview
13.8.5 Celgene Corporation Latest Developments
13.9 Dendreon Corporation
13.9.1 Dendreon Corporation Company Information
13.9.2 Dendreon Corporation Urological Cancer Drugs Product Offered
13.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Dendreon Corporation Main Business Overview
13.9.5 Dendreon Corporation Latest Developments
13.10 Ferring Pharmaceuticals
13.10.1 Ferring Pharmaceuticals Company Information
13.10.2 Ferring Pharmaceuticals Urological Cancer Drugs Product Offered
13.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Ferring Pharmaceuticals Main Business Overview
13.10.5 Ferring Pharmaceuticals Latest Developments
13.11 GlaxoSmithKline
13.11.1 GlaxoSmithKline Company Information
13.11.2 GlaxoSmithKline Urological Cancer Drugs Product Offered
13.11.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 GlaxoSmithKline Main Business Overview
13.11.5 GlaxoSmithKline Latest Developments
13.12 Indevus Pharmaceuticals Inc
13.12.1 Indevus Pharmaceuticals Inc Company Information
13.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Offered
13.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Indevus Pharmaceuticals Inc Main Business Overview
13.12.5 Indevus Pharmaceuticals Inc Latest Developments
13.13 Ipsen
13.13.1 Ipsen Company Information
13.13.2 Ipsen Urological Cancer Drugs Product Offered
13.13.3 Ipsen Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Ipsen Main Business Overview
13.13.5 Ipsen Latest Developments
13.14 Roche Healthcare
13.14.1 Roche Healthcare Company Information
13.14.2 Roche Healthcare Urological Cancer Drugs Product Offered
13.14.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Roche Healthcare Main Business Overview
13.14.5 Roche Healthcare Latest Developments
13.15 Sanofi S.A
13.15.1 Sanofi S.A Company Information
13.15.2 Sanofi S.A Urological Cancer Drugs Product Offered
13.15.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Sanofi S.A Main Business Overview
13.15.5 Sanofi S.A Latest Developments
13.16 Tolmar Inc
13.16.1 Tolmar Inc Company Information
13.16.2 Tolmar Inc Urological Cancer Drugs Product Offered
13.16.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Tolmar Inc Main Business Overview
13.16.5 Tolmar Inc Latest Developments
14 Research Findings and Conclusion
Table 1. Urological Cancer Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Urological Cancer Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Tablets
Table 4. Major Players of Injection
Table 5. Global Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
Table 6. Global Urological Cancer Drugs Sales Market Share by Type (2017-2022)
Table 7. Global Urological Cancer Drugs Revenue by Type (2017-2022) & ($ million)
Table 8. Global Urological Cancer Drugs Revenue Market Share by Type (2017-2022)
Table 9. Global Urological Cancer Drugs Sale Price by Type (2017-2022) & (USD/Pcs)
Table 10. Global Urological Cancer Drugs Sales by Application (2017-2022) & (K Pcs)
Table 11. Global Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Table 12. Global Urological Cancer Drugs Revenue by Application (2017-2022)
Table 13. Global Urological Cancer Drugs Revenue Market Share by Application (2017-2022)
Table 14. Global Urological Cancer Drugs Sale Price by Application (2017-2022) & (USD/Pcs)
Table 15. Global Urological Cancer Drugs Sales by Company (2020-2022) & (K Pcs)
Table 16. Global Urological Cancer Drugs Sales Market Share by Company (2020-2022)
Table 17. Global Urological Cancer Drugs Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Urological Cancer Drugs Revenue Market Share by Company (2020-2022)
Table 19. Global Urological Cancer Drugs Sale Price by Company (2020-2022) & (USD/Pcs)
Table 20. Key Manufacturers Urological Cancer Drugs Producing Area Distribution and Sales Area
Table 21. Players Urological Cancer Drugs Products Offered
Table 22. Urological Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Urological Cancer Drugs Sales by Geographic Region (2017-2022) & (K Pcs)
Table 26. Global Urological Cancer Drugs Sales Market Share Geographic Region (2017-2022)
Table 27. Global Urological Cancer Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Urological Cancer Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Urological Cancer Drugs Sales by Country/Region (2017-2022) & (K Pcs)
Table 30. Global Urological Cancer Drugs Sales Market Share by Country/Region (2017-2022)
Table 31. Global Urological Cancer Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Urological Cancer Drugs Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
Table 34. Americas Urological Cancer Drugs Sales Market Share by Country (2017-2022)
Table 35. Americas Urological Cancer Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 37. Americas Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
Table 38. Americas Urological Cancer Drugs Sales Market Share by Type (2017-2022)
Table 39. Americas Urological Cancer Drugs Sales by Application (2017-2022) & (K Pcs)
Table 40. Americas Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Table 41. APAC Urological Cancer Drugs Sales by Region (2017-2022) & (K Pcs)
Table 42. APAC Urological Cancer Drugs Sales Market Share by Region (2017-2022)
Table 43. APAC Urological Cancer Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Urological Cancer Drugs Revenue Market Share by Region (2017-2022)
Table 45. APAC Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
Table 46. APAC Urological Cancer Drugs Sales Market Share by Type (2017-2022)
Table 47. APAC Urological Cancer Drugs Sales by Application (2017-2022) & (K Pcs)
Table 48. APAC Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Table 49. Europe Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
Table 50. Europe Urological Cancer Drugs Sales Market Share by Country (2017-2022)
Table 51. Europe Urological Cancer Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 53. Europe Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
Table 54. Europe Urological Cancer Drugs Sales Market Share by Type (2017-2022)
Table 55. Europe Urological Cancer Drugs Sales by Application (2017-2022) & (K Pcs)
Table 56. Europe Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Urological Cancer Drugs Sales by Country (2017-2022) & (K Pcs)
Table 58. Middle East & Africa Urological Cancer Drugs Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Urological Cancer Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Urological Cancer Drugs Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Urological Cancer Drugs Sales by Type (2017-2022) & (K Pcs)
Table 62. Middle East & Africa Urological Cancer Drugs Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Urological Cancer Drugs Sales by Application (2017-2022) & (K Pcs)
Table 64. Middle East & Africa Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Urological Cancer Drugs
Table 66. Key Market Challenges & Risks of Urological Cancer Drugs
Table 67. Key Industry Trends of Urological Cancer Drugs
Table 68. Urological Cancer Drugs Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Urological Cancer Drugs Distributors List
Table 71. Urological Cancer Drugs Customer List
Table 72. Global Urological Cancer Drugs Sales Forecast by Region (2023-2028) & (K Pcs)
Table 73. Global Urological Cancer Drugs Sales Market Forecast by Region
Table 74. Global Urological Cancer Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Urological Cancer Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Urological Cancer Drugs Sales Forecast by Country (2023-2028) & (K Pcs)
Table 77. Americas Urological Cancer Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Urological Cancer Drugs Sales Forecast by Region (2023-2028) & (K Pcs)
Table 79. APAC Urological Cancer Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Urological Cancer Drugs Sales Forecast by Country (2023-2028) & (K Pcs)
Table 81. Europe Urological Cancer Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Urological Cancer Drugs Sales Forecast by Country (2023-2028) & (K Pcs)
Table 83. Middle East & Africa Urological Cancer Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Urological Cancer Drugs Sales Forecast by Type (2023-2028) & (K Pcs)
Table 85. Global Urological Cancer Drugs Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Urological Cancer Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Urological Cancer Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Urological Cancer Drugs Sales Forecast by Application (2023-2028) & (K Pcs)
Table 89. Global Urological Cancer Drugs Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Urological Cancer Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Urological Cancer Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 92. Novartis Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Novartis Urological Cancer Drugs Product Offered
Table 94. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 95. Novartis Main Business
Table 96. Novartis Latest Developments
Table 97. Pfizer Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Pfizer Urological Cancer Drugs Product Offered
Table 99. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 100. Pfizer Main Business
Table 101. Pfizer Latest Developments
Table 102. Johnson & Johnson Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Johnson & Johnson Urological Cancer Drugs Product Offered
Table 104. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 105. Johnson & Johnson Main Business
Table 106. Johnson & Johnson Latest Developments
Table 107. AstraZeneca Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. AstraZeneca Urological Cancer Drugs Product Offered
Table 109. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 110. AstraZeneca Main Business
Table 111. AstraZeneca Latest Developments
Table 112. Astellas Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Astellas Urological Cancer Drugs Product Offered
Table 114. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 115. Astellas Main Business
Table 116. Astellas Latest Developments
Table 117. Bristol-Myers Squibb Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Bristol-Myers Squibb Urological Cancer Drugs Product Offered
Table 119. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 120. Bristol-Myers Squibb Main Business
Table 121. Bristol-Myers Squibb Latest Developments
Table 122. Abbott Laboratories Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Abbott Laboratories Urological Cancer Drugs Product Offered
Table 124. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 125. Abbott Laboratories Main Business
Table 126. Abbott Laboratories Latest Developments
Table 127. Celgene Corporation Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Celgene Corporation Urological Cancer Drugs Product Offered
Table 129. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 130. Celgene Corporation Main Business
Table 131. Celgene Corporation Latest Developments
Table 132. Dendreon Corporation Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Dendreon Corporation Urological Cancer Drugs Product Offered
Table 134. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 135. Dendreon Corporation Main Business
Table 136. Dendreon Corporation Latest Developments
Table 137. Ferring Pharmaceuticals Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Ferring Pharmaceuticals Urological Cancer Drugs Product Offered
Table 139. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 140. Ferring Pharmaceuticals Main Business
Table 141. Ferring Pharmaceuticals Latest Developments
Table 142. GlaxoSmithKline Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. GlaxoSmithKline Urological Cancer Drugs Product Offered
Table 144. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 145. GlaxoSmithKline Main Business
Table 146. GlaxoSmithKline Latest Developments
Table 147. Indevus Pharmaceuticals Inc Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Offered
Table 149. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 150. Indevus Pharmaceuticals Inc Main Business
Table 151. Indevus Pharmaceuticals Inc Latest Developments
Table 152. Ipsen Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Ipsen Urological Cancer Drugs Product Offered
Table 154. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 155. Ipsen Main Business
Table 156. Ipsen Latest Developments
Table 157. Roche Healthcare Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Roche Healthcare Urological Cancer Drugs Product Offered
Table 159. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 160. Roche Healthcare Main Business
Table 161. Roche Healthcare Latest Developments
Table 162. Sanofi S.A Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Sanofi S.A Urological Cancer Drugs Product Offered
Table 164. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 165. Sanofi S.A Main Business
Table 166. Sanofi S.A Latest Developments
Table 167. Tolmar Inc Basic Information, Urological Cancer Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Tolmar Inc Urological Cancer Drugs Product Offered
Table 169. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 170. Tolmar Inc Main Business
Table 171. Tolmar Inc Latest Developments
List of Figures
Figure 1. Picture of Urological Cancer Drugs
Figure 2. Urological Cancer Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Urological Cancer Drugs Sales Growth Rate 2017-2028 (K Pcs)
Figure 7. Global Urological Cancer Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Urological Cancer Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Tablets
Figure 10. Product Picture of Injection
Figure 11. Global Urological Cancer Drugs Sales Market Share by Type in 2021
Figure 12. Global Urological Cancer Drugs Revenue Market Share by Type (2017-2022)
Figure 13. Urological Cancer Drugs Consumed in Prostate Cancer
Figure 14. Global Urological Cancer Drugs Market: Prostate Cancer (2017-2022) & (K Pcs)
Figure 15. Urological Cancer Drugs Consumed in Bladder Cancer
Figure 16. Global Urological Cancer Drugs Market: Bladder Cancer (2017-2022) & (K Pcs)
Figure 17. Urological Cancer Drugs Consumed in Kidney Cancer
Figure 18. Global Urological Cancer Drugs Market: Kidney Cancer (2017-2022) & (K Pcs)
Figure 19. Urological Cancer Drugs Consumed in Testicular Cancer
Figure 20. Global Urological Cancer Drugs Market: Testicular Cancer (2017-2022) & (K Pcs)
Figure 21. Urological Cancer Drugs Consumed in Others
Figure 22. Global Urological Cancer Drugs Market: Others (2017-2022) & (K Pcs)
Figure 23. Global Urological Cancer Drugs Sales Market Share by Application (2017-2022)
Figure 24. Global Urological Cancer Drugs Revenue Market Share by Application in 2021
Figure 25. Urological Cancer Drugs Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Urological Cancer Drugs Revenue Market Share by Company in 2021
Figure 27. Global Urological Cancer Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Urological Cancer Drugs Revenue Market Share by Geographic Region in 2021
Figure 29. Global Urological Cancer Drugs Sales Market Share by Region (2017-2022)
Figure 30. Global Urological Cancer Drugs Revenue Market Share by Country/Region in 2021
Figure 31. Americas Urological Cancer Drugs Sales 2017-2022 (K Pcs)
Figure 32. Americas Urological Cancer Drugs Revenue 2017-2022 ($ Millions)
Figure 33. APAC Urological Cancer Drugs Sales 2017-2022 (K Pcs)
Figure 34. APAC Urological Cancer Drugs Revenue 2017-2022 ($ Millions)
Figure 35. Europe Urological Cancer Drugs Sales 2017-2022 (K Pcs)
Figure 36. Europe Urological Cancer Drugs Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Urological Cancer Drugs Sales 2017-2022 (K Pcs)
Figure 38. Middle East & Africa Urological Cancer Drugs Revenue 2017-2022 ($ Millions)
Figure 39. Americas Urological Cancer Drugs Sales Market Share by Country in 2021
Figure 40. Americas Urological Cancer Drugs Revenue Market Share by Country in 2021
Figure 41. United States Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Urological Cancer Drugs Sales Market Share by Region in 2021
Figure 46. APAC Urological Cancer Drugs Revenue Market Share by Regions in 2021
Figure 47. China Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Urological Cancer Drugs Sales Market Share by Country in 2021
Figure 54. Europe Urological Cancer Drugs Revenue Market Share by Country in 2021
Figure 55. Germany Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Urological Cancer Drugs Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Urological Cancer Drugs Revenue Market Share by Country in 2021
Figure 62. Egypt Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Urological Cancer Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Urological Cancer Drugs in 2021
Figure 68. Manufacturing Process Analysis of Urological Cancer Drugs
Figure 69. Industry Chain Structure of Urological Cancer Drugs
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...